Peptide research

Retatrutide: reading the weight-loss number in a trial paper

Retatrutide trial headlines usually give one weight-loss figure, and the same trial can yield two figures. Five questions help place any figure: which analysis produced it, who was in the trial, how long it ran, whether a journal has published it and which material it describes.

The retatrutide trials guide lists each published result. The retatrutide vs tirzepatide comparison shows why two trials with similar designs still do not make a head-to-head result.

Which analysis produced the figure?

TRIUMPH-2 shows the effect of this choice. The Lancet paper reported a mean change of -18.8% for the retatrutide group with the largest change, using the treatment-regimen estimand. Lilly's news release reported -20.8% for the same group using the efficacy estimand, which represents efficacy had all randomized participants stayed on study intervention without starting prohibited weight management treatments. Sources: 2026 Lancet, PMID 42810372 and Lilly news release, July 23, 2026.

Who was in the trial?

Placebo results move with the population. In TRIUMPH-1, adults with obesity and no diabetes lost 3.9% on placebo over 80 weeks. In TRIUMPH-2, adults with obesity and type 2 diabetes lost 5.1% on placebo over the same 80 weeks. Sources: PMID 42814954 and PMID 42810372.

How long did the trial run?

Trial length changes what a figure means. The phase 2 obesity trial reported weight change at 24 and 48 weeks, and the figures grew with time in every retatrutide group. Source: 2023 New England Journal of Medicine, PMID 37366315.

Is the figure a paper or a topline release?

TRIUMPH-3 and TRIUMPH-4 have sponsor topline figures and no results paper in PubMed on October 15, 2026, so their numbers come from the sponsor's release alone. Sources: Lilly news release, July 23, 2026 and Lilly news release, December 11, 2025.

Match the material to the paper

A trial result belongs to the molecule that Lilly tested. A vial in a laboratory is documented by its own lot report. The Reta 10mg Kit listing at Curo identifies a supplier's material, and Curo's lot-certificate library and Curo's testing-method page describe how lot reports are organized.

Sources checked October 15, 2026. Reference information for laboratory research.

Wolverine peptide stack: reading a "tested together" claim

Wolverine peptide stack claims often say the two peptides were tested together. Before accepting that, a reader can ask four questions of the paper behind it. The answers decide what the result can support. The Wolverine peptide stack research page applies these questions to the two records that include BPC-

BPC-157: what FDA's 2026 briefing document covers, section by section

BPC-157 has a long paper trail in animal studies and a short one in people. FDA's briefing document for its July 2026 advisory committee, dated May 11, 2026, reviews that record in detail. This post walks through its sections and says what each one covers. Why FDA

TB-500 Peptide: Matching a Listing Name to FDA, PubChem and WADA Records

TB-500 peptide listings rarely agree on what the name covers. This note walks through the public records that tie the name to a specific molecule and shows what each record confirms. The TB-500 peptide guide gives the same material question by question. Step 1: the sequence The reference

Tesamorelin peptide: what an FDA label does and does not tell you about a vial

Tesamorelin peptide is unusual among research compounds because a finished prescription drug made from it has an FDA label. Three documents get mixed up here: the label for the finished product, a supplier's listing for a vial, and a lot report for one lot. Each one records its